2020年02月19日讯 /生物谷BIOON/ --辉瑞（Pfizer）近日宣布，欧盟委员会（EC）已批准Vyndaqel（tafamidis），该药是一种每日一次的61mg ...

eplontersen是一种配体偶联反义(LICA)药物，可减少转甲状腺素蛋白（TTR）的产生。 ATTR淀粉样变性（图片来源：clevelandclinic.org ...

CAMBRIDGE, Mass., June 09, 2025--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the European Commission ...

Novo Nordisk has struck a $1.2 billion deal to buy Prothena’s ATTR amyloidosis program, which was stalled by the pandemic last year. The deal will see Novo pay $100 million in upfront and near-term ...

“Estimates show approximately 100,000 people are affected by ATTR amyloidosis across Europe, most with cardiomyopathy, so this approval marks a critical step toward addressing this underserved patient ...

Intellia Therapeutics, Inc. announced key operational and financial updates for the first quarter of 2025, highlighting significant progress in its clinical trials. The company is on track to complete ...